These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
83 related articles for article (PubMed ID: 29027820)
1. Using Cost-Effectiveness Analysis to Quantify the Value of Genomic-Based Diagnostic Tests: Recommendations for Practice and Research. Spackman E; Hinde S; Bojke L; Payne K; Sculpher M Genet Test Mol Biomarkers; 2017 Dec; 21(12):705-716. PubMed ID: 29027820 [TBL] [Abstract][Full Text] [Related]
2. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis. Mauskopf JA; Sullivan SD; Annemans L; Caro J; Mullins CD; Nuijten M; Orlewska E; Watkins J; Trueman P Value Health; 2007; 10(5):336-47. PubMed ID: 17888098 [TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analyses of genetic and genomic diagnostic tests. Payne K; Gavan SP; Wright SJ; Thompson AJ Nat Rev Genet; 2018 Apr; 19(4):235-246. PubMed ID: 29353875 [TBL] [Abstract][Full Text] [Related]
4. A scoping study to explore the cost-effectiveness of next-generation sequencing compared with traditional genetic testing for the diagnosis of learning disabilities in children. Beale S; Sanderson D; Sanniti A; Dundar Y; Boland A Health Technol Assess; 2015 Jun; 19(46):1-90. PubMed ID: 26132578 [TBL] [Abstract][Full Text] [Related]
5. Toward health technology assessment of whole-genome sequencing diagnostic tests: challenges and solutions. Payne K; Eden M; Davison N; Bakker E Per Med; 2017 May; 14(3):235-247. PubMed ID: 29767583 [TBL] [Abstract][Full Text] [Related]
6. Telemedicine for the Medicare population: pediatric, obstetric, and clinician-indirect home interventions. Hersh WR; Wallace JA; Patterson PK; Shapiro SE; Kraemer DF; Eilers GM; Chan BK; Greenlick MR; Helfand M Evid Rep Technol Assess (Summ); 2001 Aug; (24 Suppl):1-32. PubMed ID: 11569328 [TBL] [Abstract][Full Text] [Related]
7. Valuation of Health and Nonhealth Outcomes from Next-Generation Sequencing: Approaches, Challenges, and Solutions. Regier DA; Weymann D; Buchanan J; Marshall DA; Wordsworth S Value Health; 2018 Sep; 21(9):1043-1047. PubMed ID: 30224107 [TBL] [Abstract][Full Text] [Related]
8. How has the impact of 'care pathway technologies' on service integration in stroke care been measured and what is the strength of the evidence to support their effectiveness in this respect? Allen D; Rixson L Int J Evid Based Healthc; 2008 Mar; 6(1):78-110. PubMed ID: 21631815 [TBL] [Abstract][Full Text] [Related]
9. Genomic sequencing in clinical practice: applications, challenges, and opportunities. Krier JB; Kalia SS; Green RC Dialogues Clin Neurosci; 2016 Sep; 18(3):299-312. PubMed ID: 27757064 [TBL] [Abstract][Full Text] [Related]
10. Genomic medicine and risk prediction across the disease spectrum. Kotze MJ; Lückhoff HK; Peeters AV; Baatjes K; Schoeman M; van der Merwe L; Grant KA; Fisher LR; van der Merwe N; Pretorius J; van Velden DP; Myburgh EJ; Pienaar FM; van Rensburg SJ; Yako YY; September AV; Moremi KE; Cronje FJ; Tiffin N; Bouwens CS; Bezuidenhout J; Apffelstaedt JP; Hough FS; Erasmus RT; Schneider JW Crit Rev Clin Lab Sci; 2015; 52(3):120-37. PubMed ID: 25597499 [TBL] [Abstract][Full Text] [Related]
11. [Genomic Tests: From Basic Research to Clinical Practice]. Nakatani K; Mochiki I Rinsho Byori; 2015 Mar; 63(3):377-83. PubMed ID: 26524861 [TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis in relation to budgetary constraints and reallocative restrictions. Adang E; Voordijk L; Jan van der Wilt G; Ament A Health Policy; 2005 Oct; 74(2):146-56. PubMed ID: 16153475 [TBL] [Abstract][Full Text] [Related]
13. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Sullivan SD; Mauskopf JA; Augustovski F; Jaime Caro J; Lee KM; Minchin M; Orlewska E; Penna P; Rodriguez Barrios JM; Shau WY Value Health; 2014; 17(1):5-14. PubMed ID: 24438712 [TBL] [Abstract][Full Text] [Related]
14. Influence of genomics on adjuvant treatments for pre-invasive and invasive breast cancer. Abu-Khalf M; Pusztai L Breast; 2013 Aug; 22 Suppl 2():S83-7. PubMed ID: 24074799 [TBL] [Abstract][Full Text] [Related]
15. The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report. McGhan WF; Al M; Doshi JA; Kamae I; Marx SE; Rindress D Value Health; 2009; 12(8):1086-99. PubMed ID: 19744291 [TBL] [Abstract][Full Text] [Related]
16. Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective: the ISPOR Drug Cost Task Force report--Part II. Garrison LP; Mansley EC; Abbott TA; Bresnahan BW; Hay JW; Smeeding J Value Health; 2010; 13(1):8-13. PubMed ID: 19883405 [TBL] [Abstract][Full Text] [Related]
17. A research roadmap for complementary and alternative medicine - what we need to know by 2020. Fischer F; Lewith G; Witt CM; Linde K; von Ammon K; Cardini F; Falkenberg T; Fønnebø V; Johannessen H; Reiter B; Uehleke B; Weidenhammer W; Brinkhaus B Forsch Komplementmed; 2014; 21(2):e1-16. PubMed ID: 24851850 [TBL] [Abstract][Full Text] [Related]
18. Assessing the Joint Value of Genomic-Based Diagnostic Tests and Gene Therapies. Gavan SP; Lu CY; Payne K J Pers Med; 2019 May; 9(2):. PubMed ID: 31117188 [TBL] [Abstract][Full Text] [Related]
19. The influence of time horizon on results of cost-effectiveness analyses. Kim DD; Wilkinson CL; Pope EF; Chambers JD; Cohen JT; Neumann PJ Expert Rev Pharmacoecon Outcomes Res; 2017 Dec; 17(6):615-623. PubMed ID: 28504026 [TBL] [Abstract][Full Text] [Related]